Strategies for Phosphate Control in Patients With CKD

Area of Science:

• Nephrology
• Endocrinology
• Biochemistry

Background:

• Hyperphosphatemia is a frequent complication in chronic kidney disease (CKD), especially with renal replacement therapy.
• Elevated serum phosphate is linked to adverse outcomes, mortality, bone disease, and cardiovascular issues in CKD patients.
• Phosphate homeostasis involves intricate interactions between kidneys, gut, bone, and endocrine systems, influenced by diet and food additives.

Purpose of the Study:

• To review current treatment strategies for hyperphosphatemia in CKD.
• To highlight practical challenges, limitations, and the benefit-risk profiles of existing therapies.
• To discuss the ongoing debate regarding the impact of phosphate-lowering interventions on clinical outcomes.

Main Methods:

• Review of current literature on hyperphosphatemia management in CKD.
• Discussion of dietary phosphate restriction.
• Analysis of intestinal phosphate absorption reduction strategies.
• Evaluation of phosphate removal via dialysis.
• Examination of renal osteodystrophy management.

Main Results:

• Current management of hyperphosphatemia in CKD is often difficult and unsuccessful.
• Evidence supporting the clinical benefits of phosphate-lowering interventions on hard outcomes remains debated.
• Various approaches exist, including dietary changes, absorption reduction, dialysis, and managing bone complications.

Conclusions:

• Effective control of hyperphosphatemia in CKD remains a significant clinical challenge.
• A comprehensive understanding of phosphate regulation and treatment limitations is crucial.
• Further research is needed to clarify the impact of phosphate-lowering therapies on patient outcomes.